Trending Topic

14 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Kate Clair Cruden Hughes, Amy Hai Yan Chan

Asthma affects nearly 300 million people worldwide.1 Despite a notable decline in age-standardized prevalence, mortality and disability-adjusted life years over the past three decades, the burden of asthma remains high in many countries including low-middle-income countries.2 Climate change is also predicted to significantly impact asthma and other respiratory-related conditions, as rising global temperatures lead to longer pollen […]

Search Results

Showing Results for pulmonary function test

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

Future Leader, Dr Michelle Korah-Sedgwick discusses her innovative work at the intersection of immunology and respiratory care, focusing on uncovering immune deficiencies in chronic lung disease. She shares insights on personalized treatment approaches, the value of clinical vigilance, and how registries are transforming care for patients with complex respiratory conditions.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, Professor Irene Higginson, Director of Better Health and Care Futures at King’s College London, discusses the complex challenges of managing breathlessness. She explores non-pharmacological strategies, the value of multidisciplinary care, and how the Breathlessness Support Services at KCL are transforming patient support. Tune in for expert insights and a look at future directions in breathlessness research and care.

Mark CompleteCompleted
BookmarkBookmarked

The Global Initiative for Asthma (GINA) has released its 2024 update on asthma management and prevention. This report, authored by the GINA Science Committee, brings significant updates on various topics crucial for effective asthma management.

Mark CompleteCompleted
BookmarkBookmarked

The European Commission has approved dupilumab (Regeneron and Sanofi)) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils.

Mark CompleteCompleted
BookmarkBookmarked

Approximately half of all smokers will develop chronic obstructive pulmonary disease (COPD), with a disease progression over several years before the spirometric threshold for diagnosis is reached.1 There is, therefore, a clear benefit in identifying patients with COPD as early ...

Mark CompleteCompleted
BookmarkBookmarked

The nasal airway serves as the primary entry point of air and oxygen into the body. It serves critical functions, such as providing a physical barrier against external irritants and pathogens and warming and humidifying incoming air.1 Consequently, disorders of ...

Mark CompleteCompleted
BookmarkBookmarked

Pentraxin-2 is a member of the pentraxin family of proteins, which includes C-reactive protein (CRP), pentraxin-2 and pentraxin-3.1–3 When initially discovered and characterized, pentraxin-2 was known as serum amyloid P (SAP) due to its isolation from amyloid deposits in humans; ...

Mark CompleteCompleted
BookmarkBookmarked

Paediatric sleep-disordered breathing Sleep-disordered breathing (SDB) is defined as the disruption of normal respiration and ventilation while asleep.1 SDB encompasses multiple sleep disturbances, ranging from mild snoring to obstructive sleep apnoea (OSA).1,2 OSA is characterized by episodic partial or complete ...

Mark CompleteCompleted
BookmarkBookmarked

Interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by inflammation and/or fibrosis.1 Pulmonary fibrosis develops due to repeated cycles of injury and impaired repair with fibroblast activation and migration with the resultant deposition of extracellular matrix ...

Mark CompleteCompleted
BookmarkBookmarked

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are the dominant cause of the worsening and high mortality of chronic obstructive pulmonary disease (COPD), and are associated with higher healthcare costs as part of COPD management. AECOPD is characterized by ...

Mark CompleteCompleted
BookmarkBookmarked
Laurence Désy, Philippe Lachapelle, Simon Couillard

The topic of the carbon footprint of human activities is one frequently discussed worldwide. There have been conscious efforts across multiple fields, including healthcare, to reduce their carbon footprint. In Canada, 4.6% of greenhouse gases (GHG) are manufactured by the healthcare ...

Mark CompleteCompleted
BookmarkBookmarked

The natural progression of neuromuscular disease (NMD) inevitably involves respiratory system failure. Increasing respiratory muscle weakness causes worsening hypoventilation, leading to hypercapnia and, eventually, hypoxemia. The American College of Chest Physicians (CHEST) recently published guidelines on the respiratory management of ...

Mark CompleteCompleted
BookmarkBookmarked
Jonathan Alkalai, Anne Iwata, Elinor Lee

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary syndrome with a prevalence of approximately seven cases per 1 million individuals.1,2 PAP affects people of all age, sex, race and socioeconomic status. Based on the largest population studies conducted in the United ...

Mark CompleteCompleted
BookmarkBookmarked

Alpha-1 antitrypsin deficiency (AATD)-lung disease (LD) is a rare genetic disease caused by a deficiency of the alpha-1 antitrypsin (AAT) protein in the blood and lungs. Loss of the AAT protein reduces inhibition of the proteases, specifically neutrophil elastase, ...

Mark CompleteCompleted
BookmarkBookmarked

The definition of chronic obstructive pulmonary disease (COPD) has recently been reformulated better to encompass the heterogeneous nature of this lung condition.1 The new definition is broader, includes risk factors other than smoking, and aims to improve the diagnosis, management ...

Mark CompleteCompleted
BookmarkBookmarked

There is a genuine interest on the part of researchers and the pharmaceutical industry in developing so-called ‘bifunctional’ drugs – that is, single molecules with two different primary pharmacological actions.1,2 In this context, single molecules that are capable of simultaneously inducing ...

Load More...
Close Popup